X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

PRFX

Closed

Painreform ltd

1.4
0.0 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.44
Day's Range: 1.37 - 1.44
Send
When Written:
 
0.6301
Painreform Ltd is a clinical-stage specialty pharmaceutical company that focuses on the development of extended-release formulations of drugs in the field of pain management. The company's proprietary technology platform, called PRF-110, is designed to enhance the efficacy and safety of existing drugs by improving their pharmacokinetic and pharmacodynamic properties. Painreform's lead product candidate, PRF-110, is an extended-release formulation of bupivacaine, a local anesthetic used for postoperative pain management. The company is also developing PRF-120, an extended-release formulation of diclofenac, a nonsteroidal anti-inflammatory drug used for the treatment of acute and chronic pain. Painreform is headquartered in Herzliya, Israel, and was founded in 2007.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X